DNDi, partners aim to bring cheaper HCV combo to Latin America

The Drugs for Neglected Diseases initiative said it will partner with three pharmaceutical companies and a non-profit to sell a cheaper HCV regimen in Latin America. HCV patients pay at least $7,000 in Argentina, $12,000 in Chile and

Read the full 388 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE